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Effect of Metformin or Gliclazide on Lipid Peroxidation
and Antioxidant Levels in Patients with Diabetes
Mellitus
Aim: The association between oxidative stress and diabetic complications is well known. The main goal of
antidiabetic therapy is to prevent the complications of diabetes. Gliclazide (sulfonylurea) and metformin
(biguanide) are two oral antidiabetic drugs that have been proven to prevent diabetic complications. In this
study, we aimed to investigate the antioxidant effects of gliclazide or metformin.
Materials and Methods: In this study, we evaluated 46 patients with type 2 diabetes mellitus. The patients
were divided into three groups according to their treatment modality of gliclazide, metformin, or diet.
Erythrocyte glutathione peroxidase (Gpx), glutathione S-transferase (GST), and catalase (CAT) activities and
malondialdehyde (MDA) and glutathione (GSH) levels of the patients were measured and compared.
Results: The erythrocyte Gpx, GST, and CAT activities were significantly higher, whereas MDA levels were
significantly lower in both gliclazide and metformin groups when compared with the diet group. There was
no statistically significant difference between gliclazide and metformin groups in terms of activities of
antioxidant enzymes and levels of MDA. In addition, GSH levels were not different among the groups.
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Conclusions: The data obtained in this study showed that gliclazide or metformin administration may
decrease oxidative stress, and both drugs had similar effects.
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Diyabetli Hastalarda Gliklazid veya Metformin’in Lipid Peroksidasyonu ve
Antioksidan Düzeyleri Üzerine Etkisi
Amaç: Oksidatif stress ve diyabetin komplikasyonları arasındaki ilişki iyi bilinir. Antidiyabetik tedavinin temel
amacı diyabetin komplikasyonlarından korumaktır. Diyabetin komplikasyonlarından koruduğu kanıtlanmış
olan sülfanilüre gliklazid ve biguanid metformin iki oral antidiyabetik ilaçtır. Bu çalışmada gliklazid veya
metformin’in antioksidan özelliklerini araştırmayı amaçladık.
Yöntem ve Gereç: Bu çalışmada 46 tip 2 diyabetli hasta değerlendirildi. Hastalar gliklazid, metformin veya
sadece diyet almalarına göre 3 gruba ayrıldı. Eritrosit glutatyon peroksidaz (Gpx), glutatyon S-transferaz
(GST) ve katalaz (CAT) aktiviteleri, lipid peroksidasyon göstergesi olarak malondialdehid (MDA) ve glutatyon
(GSH) düzeyleri ölçüldü ve karşılaştırıldı.
Bulgular: Sadece diyet alan grupla karşılaştırıldığında hem gliklazid hem de metformin grubunda eritrosit
Gpx, GST ve CAT aktiviteleri anlamlı olarak daha yüksekken, MDA düzeyi ise anlamlı olarak daha düşüktü.
Antioksidan enzim aktiviteleri ve MDA ile GSH düzeyleri açısından gliklazid ve metformin grupları arasında
istatistiksel anlamlı bir fark yoktu.
Sonuç: Çalışmadan elde edilen veriler gliklazid veya metformin tedavisinin oksidatif stresi azaltabileceğini ve
bu etkinin gliklazid ve metformin gruplarında benzer olduğunu göstermiştir.
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It is well known that oxidative stress plays important roles in the pathophysiology of
many diseases such as diabetes, Behçet’s disease, and rheumatoid arthritis, and impairs
various cellular functions (1-3). To control the flux of reactive oxygen species (ROS),
aerobic cells have antioxidant enzymes such as superoxide dismutase (SOD), glutathione
peroxidase (Gpx), catalase (CAT), glutathione S-transferase (GST), as well as nonenzymatic antioxidants such as glutathione (GSH) and vitamins C and E to defend
themselves against oxidative stress. SOD catalyzes the dismutation of the superoxide
anion into hydrogen peroxide (H2O2). H2O2 can be transformed into H2O and O2 by CAT
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MEMİŞOĞULLARI, R et al.

Antioxidant Effects of Gliclazide and Metformin

or into H2O by Gpx. Gpx is a selenoprotein, which reduces
lipidic or nonlipidic hydroperoxides as well as H2O2 while
oxidizing GSH (1-4).
Gliclazide and metformin have different mechanisms
to reduce glycemia. Gliclazide, a second-generation
sulfonylurea that possesses a unique azabicyclo-octyl ring,
is reported to act as a general free radical scavenger in
vitro (5-8). It has also been reported that metformin has
an antioxidant activity (7-12). In our literature search,
although there are a few reports about the antioxidant
effects of gliclazide or metformin separately, we could
not find any human study evaluating both gliclazide and
metformin on the basis of lipid peroxidation and
antioxidant enzymes, or comparing them with respect to
their effect on antioxidant and oxidant parameters. Thus,
we planned to evaluate both gliclazide and metformin on
the basis of lipid peroxidation and antioxidant enzymes.
Materials and Methods
In this study, we evaluated 46 patients with type 2
diabetes mellitus. The patients were divided into three
groups according to their treatment modalities. Sixteen
patients were administered gliclazide, 15 patients were
treated with metformin and 15 patients received only diet
treatment. Mean duration of diabetes in these groups was
12.2 ± 0.24, 13.4 ± 0.39 and 11.3 ± 0.27 (mean ± SE)
years, respectively. The patients selected for diet therapy
were those who discontinued their therapy against
physician advice or who rejected any medication. None of
the patients was a smoker. None consumed alcohol,
received any medication except gliclazide or metformin,
or had any other chronic disease. Erythrocyte Gpx, GST,
and CAT activities and malondialdehyde (MDA), as a lipid
peroxidation marker, and GSH levels of the patients were
measured and compared.
Biochemical Measurements
After the collection of blood samples into tubes
containing EDTA, erythrocytes were washed 3 times with
serum physiologic (0.9% NaCl). Erythrocyte sediments
were prepared for the determination of Gpx, GST, and
CAT activities and MDA and GSH levels. Erythrocytes
were then hemolyzed with diluted deionized water (50fold), and the analyses were carried out on this
hemolyzed supernatant fraction. Hemoglobin (Hb) values
were measured with a GEN-S counter (Beckman-Coulter,
USA). Hemolyzed samples were kept at –80°C until
biochemical determinations.
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Venous blood was also collected in vacutainers
without additive for routine biochemical determination,
allowed to clot for 30 min at room temperature, and
centrifuged at 3000 x g for 5 min to obtain serum.
Serum aliquots were stored at -80°C until biochemical
analyses.
Serum glucose (GLU) levels were measured with an
autoanalyzer (Hitachi 717 Analyser, Hitachi, Japan) using
commercial kits. Hemoglobin A1C (HbA1C) levels were
measured by high performance liquid chromatographic
assay (Hi-Auto A1C HA 8121; Kyoto Dai-ichi Kagaku,
Japan).
Gpx activity was measured according to the Paglia and
Valentina method (13). Gpx activity was expressed as U/g
Hb. CAT activity was measured in hemolysates at 20oC,
according to the method of Aebi (14). Using a molar
-1
-1
extinction coefficient of 43.6 M cm , the rate of the
first 30 s was used to calculate the activity. CAT activity
was expressed as U/mg Hb. Virtually all of the nonprotein sulfhydryl groups of erythrocytes are in the form
of reduced GSH. 5,5’- Dithio bis (2-nitrobenzoic acid) is a
disulfide chromogen that is readily reduced by sulfhydryl
compounds to an intensely yellow compound. The
absorbance of the reduced chromogen is measured at
412 nm and is directly proportional to the GSH
concentration (15). GSH activity was expressed as
mmol/g Hb. GST activity of the supernatant was
measured by using 1-chloro-2,4-dinitrobenzene (16).
The activity was expressed as U/g Hb. MDA was
determined on the basis of spectrophotometric
absorbance measurement of the pink-colored product of
the thiobarbituric acid reactive substance (TBARS)
complex (17). Total TBARS was expressed as MDA.
Results are expressed as nmol/g Hb. These measurements
were carried out using a spectrophotometer (CECIL CE
3041, Cambridge, UK).
Statistical Analysis
The findings were expressed as the means ± SE
(standard error). Firstly, the data were analyzed with
Kolmogorov-Smirnov test for parametric or nonparametric discrimination. The data showed parametric
distribution according to this test. Statistical analyses
were undertaken using one-way ANOVA. LSD (least
significant difference) multiple range test was used to
compare the mean values (acceptable significance was
recorded when p values were <0.05). Correlation
analyses were undertaken using Pearson’s rank
correlation test. Statistical analysis was performed with
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Statistical Package for the Social Sciences for Windows
(SPSS, version 10.0, Chicago, IL, USA).
Results
Comparisons of the groups are shown in Table . There
was no statistically significant difference among groups in
terms of GLU, HbA1C, and body mass index (BMI). As
shown in Table , the erythrocyte Gpx, CAT, and GST
activities were significantly higher; in contrast, MDA
levels were significantly lower in both gliclazide and
metformin groups than in the diet group (Table ). There
was no statistically significant difference between
gliclazide and metformin groups in terms of activities of
antioxidant enzymes and levels of MDA. In addition, GSH
levels did not differ between the groups.
In correlation analysis, there was a negative
correlation between GSH and GLU level (r= -0.65; P <
0.01) in the metformin group. A positive correlation
between MDA and HbA1C (r= 0.75; P < 0.001) and a
negative correlation between Gpx and MDA level (r= 0.54; P < 0.05) were determined in the diet group.
Discussion
The data obtained in this study showed that gliclazide
or metformin had an oxidative stress-decreasing effect,
apart from their anti-hyperglycemic effect. This effect
was similar in both metformin and gliclazide groups.
In previous studies, free radical scavenging properties
of gliclazide were reported and these properties are not
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shared by other sulfonylureas, such as glibenclamide or
tolbutamide (5,18). In type 2 diabetes, gliclazide has been
reported to reduce in vitro low-density lipoprotein (LDL)
oxidation and to reduce both endothelial and monocyte
cell-mediated LDL oxidation and monocyte adhesion to
endothelial cells in vitro (5-7).
Metformin is a biguanide antihyperglycemic agent
used for the management of type 2 diabetes. Several
studies have shown reduced cardiovascular-related
mortality rates in metformin-receiving patients. These
observations suggest that metformin might have an
additional mechanism of action beyond its
antihyperglycemic properties (7-11,19). Khouri et al.
.(20) reported that metformin does not scavenge O 2
.
radicals, but is able to react with OH radical. Their results
obtained with an in vitro model allow assuming that
metformin, at a molecular level, is not a very good
scavenger of ROS. Consequently, it seems that metformin
would certainly exert its in vivo antioxidant activity by
different pathways other than the simple free radical
scavenging action, such as increasing the antioxidant
enzyme activities, decreasing the markers of lipid
peroxidation and inhibiting the formation of advanced
glycation end products (20).
Measurement of TBARS is probably the most widely
used assay in biochemical studies. Alper et al. (21)
reported that gliclazide treatment alone decreased liver
tissue MDA level significantly; however, it was unable to
decrease plasma MDA levels. We have found that MDA
levels were lower in both the gliclazide and metformin
groups than in the diet group.

Table. Results of study groups (mean ± SE).

Gpx (Ug-1Hb)
-1

Gliclazide Group
n = 16

Metformin Group
n = 15

Diet Group
n = 15

41.13 ± 1.95a

39.51 ± 1.94 a

29.20 ± 1.99

CAT (Umg Hb)

2.44 ± 0.06

GSH (mmolg-1Hb)

8.95 ± 0.48

-1

GST (Ug Hb)
MDA (nmolg-1Hb)

a

2.57 ± 0. 10

a

8.49 ± 0.87

2.09 ± 0.16
8.29 ± 0.58

26.81 ± 1.6

a

31.67 ± 2.58

11.5 ± 0.23

a

11.5 ± 0.33 a

13.2 ± 0.55

GLU (mg/dL)

143.8 ± 11.5

147.3 ± 12.6

160.8 ± 15.3

HbA1C (%)

7.5 ± 0.3

7.3 ± 0.4

8.2 ± 0.2

26.9 ± 1.2

27.1 ± 0.8

26.7 ± 1.0

2

BMI (kg/m )

a

15.87 ± 2.71

a

: P < 0.05, when compared with diet group
Gpx: Glutathione peroxidase. CAT: Catalase. GSH: Glutathione. GST: Glutathione S- transferase.
MDA: Malondialdehyde. GLU: Glucose. HbA1C: Hemoglobin A1C. BMI: Body mass index.
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The levels of erythrocyte antioxidants such as GSH,
Gpx, GST, and CAT tend to decrease, and MDA tends to
increase in diabetic patients (2). In our study, Gpx, GST,
and CAT activities were higher in the gliclazide and
metformin groups than in the diet group. Although GSH
levels were higher in both metformin and gliclazide
groups, this was not statistically significant when
compared with the diet group. That is to say, antioxidant
effects of gliclazide are similar to those of metformin.
Pavlovic et al. (22) reported that metformin monotherapy
decreased erythrocyte MDA levels and increased
erythrocyte CAT activity and GSH level. However, we could
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not determine higher GSH levels with metformin therapy.
We found that there was a positive correlation between
MDA and HbA1C level and a negative correlation between
MDA level and Gpx activity in the diet group.
ROS have been reported to be affected with better
glycemic control (2,3). However, there was no statistical
difference between the groups in terms of glycemic
control. Therefore, the results of this study could be
interpreted as independent from the effect of glycemic
control. Nevertheless, we think that the subject still
requires further studies with larger cohorts before
reaching a final decision.
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